SynthesisFrontiers in immunology2025
Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative effectiveness and safety of robotic versus laparoscopic liver resection for benign liver diseases: a systematic review and meta-analysis.BMC gastroenterology · 2026Pooled it
- Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn's Disease.Diseases (Basel, Switzerland) · 2026Article
- Short-term risk and long-term incidence rate of herpes zoster with upadacitinib in patients with atopic dermatitis and psoriatic arthritis: a systematic review and meta-analysis.Postepy dermatologii i alergologii · 2026Review
- Case Report: Near-complete resolution of nail psoriasis with upadacitinib in a pediatric patient.Frontiers in immunology · 2026Article
- Fatal Suicide Attempt with Upadacitinib (RinvoqReports (MDPI) · 2025Article
- A disproportionality analysis of FDA adverse event reporting system (FAERS) events for filgotinib.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: There is a growing array of options for the treatment of immune-mediated inflammatory diseases (IMIDs). To explore upadacitinib's efficacy and safety in autoimmune disease treatment, we conducted this study. Methods: Pubmed, Web of Science and Embase were searched for randomized controlled trials related to the treatment of upadacitinib from the databases' inception to May 31, 2024. After literature screening, data extraction and bias assessment by two investigators, RevMan 5.3 or Stata 17.0 software was used for meta-analysis. Results: 45 records across the following five types of IMIDs were obtained. For rheumatoid arthritis (RA), upadacitinib 15 mg outperformed placebo, methotrexate and adalimumab (ADA) in 20% improvement according to ACR criteria (ACR20) and 28-joint disease activity score (DAS28) ( Conclusions: Upadacitinib is effective in treating IMIDs like RA, axSpA, PsA, CD, and UC. Though well-tolerated generally, its safety in infection especially HZ needs caution. Thorough assessment, monitoring and individualized dosing are vital to manage potential AEs. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42024569370.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.